Engineered Salmonella Therapy Reduced Tumors in Mice, Study Finds
Researchers at Jeonbuk National University engineered a Salmonella strain to deliver two anticancer components in mouse experiments. The treatment reduced tumor mass and volume and was linked to fewer cancer cells in the lungs, liver and spleen, but the findings do not establish safety or effectiveness in people.

A research team at Jeonbuk National University developed a dual-action bacterial cancer therapy that reduced tumors in mice, combining a modified Salmonella strain with two anticancer components. The findings point to a possible way to target cancer cells and stimulate immune activity, but the experiments do not establish that the treatment is safe or effective in people.
The engineered strain, JOL3136, carried instructions to produce apoptin inside cancer cells and a carcinoembryonic antigen (CEA) epitope protein in the bacteria. The team led by Professor John Hwa Lee modified the bacterium and passaged it in tumor-bearing mice to improve its ability to localize in tumors.
In tests using 4T1 cells, a highly metastatic mouse breast cancer cell line, JOL3136-treated cells showed more early and late apoptosis, or cell death, than untreated cells and cells given bacterial-vector controls.
The mouse results were notable.
Mice with 4T1 tumors received four weekly doses of a control solution, the bacterial vector or JOL3136. The treatment significantly reduced tumor mass and volume compared with both control groups. Tumor-volume reduction in the JOL3136 group exceeded that of the vector-control group by more than 200%, the researchers reported.
In a separate experiment, researchers found significantly fewer labeled cancer cells in the lungs, liver and spleen of mice treated with JOL3136 than in control mice. The treatment was also associated with increased CD49b-positive lymphocytes and interferon-gamma, an immune-signaling protein.
Lee said the approach pairs a delivery system with components intended to attack cancer cells and prompt an immune response. “Our approach combines a bacterial delivery vehicle with apoptin to promote cancer-cell death and CEA epitopes to stimulate antitumor immunity,” he said.
The study did not establish how much each component contributed to the results. Lee said the bacterial carrier could be modified to deliver other therapeutic candidates, but further work is needed before the treatment could be considered for clinical use.
“Before clinical use can be considered, we need stronger safety safeguards and further evaluation in models that better represent human disease,” Lee said.
The study was published in Biomedicine & Pharmacotherapy on September 1, 2026. The findings remain limited to mouse models, and the researchers said live Salmonella-based treatments require safeguards against infection.
Take the quizWhat Kind of Holiday Spender Are You? Take the Black Friday QuizStart →
Lifestyle7 Signs Your Social Battery Is Running Low (and Why You Keep Cancelling Plans)
Lifestyle · Food & HealthThanksgiving Food Safety: How Long Leftovers Last and the Safe Turkey Temperature
Lifestyle7 Quiet Habits of Emotionally Intelligent People, According to Psychologists
LifestylePeople Who Don’t Like Celebrating Their Birthday Often Share These 7 Traits




















